The department employed a maneuver that could protect the president from legal and financial consequences in a series of ...

The first months of President Trump’s second term have been characterized by a flurry of activity. The New York Times talked ...

Vertex Pharmaceuticals Incorporated ... ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Connections is one of the best puzzle games from the New York Times. The game tasks you with categorizing a pool of 16 words into four secret (for now) groups by figuring out how the words relate ...

Despite some notable successes, including US approval in January of a nonopioid painkiller by Boston biotech Vertex ... Eric Lee / The New York Times “That’s a concern I’d never heard ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.